Format

Send to

Choose Destination
Clin Genitourin Cancer. 2018 Nov 16. pii: S1558-7673(18)30510-X. doi: 10.1016/j.clgc.2018.11.002. [Epub ahead of print]

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.

Author information

1
Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
2
Laboratory for Translational Genetics, Department of oncology, KU Leuven, Leuven, Belgium; Vesalius Research Center, VIB, Leuven, Belgium.
3
Inserm UMR1162 Génomique Fonctionnelle des Tumeurs Solides, Université Paris-5 René Descartes, Paris, France.
4
Department of Medical Oncology, AZ Groeninge, Kortrijk, Belgium; Faculty of Health, Social Care, and Education, Anglia Ruskin University, Chelmsford, UK.
5
Department of Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
6
Department of Medical Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Bruxelles, Belgium.
7
Department of Medical Oncology, CHU Ambroise Paré, Mons, Belgium.
8
Department of Urology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
9
Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgium.
10
Department of Medical Oncology, Georges Pompidou European Hospital, Université Paris-5 René Descartes, Paris, France.
11
Department of Urology, Georges Pompidou European Hospital, Université Paris-5 René Descartes, Paris, France.
12
Department of Medical Oncology, St. Nikolaus-Hospital Eupen, Eupen, Belgium.
13
Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Inserm UMR1162 Génomique Fonctionnelle des Tumeurs Solides, Université Paris-5 René Descartes, Paris, France. Electronic address: benoit.beuselinck@uzleuven.be.

Abstract

BACKGROUND:

There are no validated markers that predict response or resistance in patients with metastatic clear-cell renal cell carcinoma (mccRCC) treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors such as sunitinib and pazopanib. Recently, single nucleotide polymorphism (SNP) rs2981582 in Fibroblast Growth Factor Receptor 2 (FGFR2) was found to be associated with clinical outcome in patients with mccRCC treated with pazopanib and sunitinib. We aimed to validate these findings in patients treated with sunitinib.

MATERIALS AND METHODS:

Germline DNA was collected in patients with mccRCC starting first-line systemic therapy with sunitinib. SNP rs2981582 in FGFR2 C>T was genotyped. Association of the genotype with response rate, tumor shrinkage, median progression-free survival (mPFS), and median overall survival (mOS) was studied.

RESULTS:

We collected clinical data from 154 patients with available germline DNA. Baseline prognostic markers were well-balanced between both subgroups. Patients with the TT genotype had a poorer outcome compared with patients with the CT/CC genotype. The median shrinkage of selected tumor target lesions during treatment with sunitinib was -16% versus -31% (P = .002), mPFS was 8 versus 15 months (P = .0007), and mOS was 22 versus 33 months (P = .04), respectively. On multivariate analysis, rs2981582 remained an independent predictor of PFS (hazard ratio, 2.858; 95% confidence interval, 1.659-4.923; P < .0001) and OS (hazard ratio, 1.795; 95% confidence interval, 1.003-3.212; P = .049).

CONCLUSION:

Polymorphism rs2981582 in FGFR2 is correlated to PFS and OS in patients with mccRCC treated with sunitinib. Prospective validation of the impact of this SNP is warranted.

KEYWORDS:

Angiogenesis inhibitor; Biomarker; Outcome; Prognosis; Single nucleotide polymorphisms

PMID:
30527746
DOI:
10.1016/j.clgc.2018.11.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center